Serina Therapeutics Gross Profit

Serina Therapeutics (SER) currently reports a gross profit of $-23K as of June 2026. That compares with $110K in the prior-year period — down 120.2% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Serina Therapeutics's gross profit history and peer comparisons.

Serina Therapeutics's gross profit decreased from $110K to $-23K — a 120.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Serina Therapeutics's gross profit of $-23K is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Serina Therapeutics reported $-23K in gross profit as of June 2026. That compares with $110K in the prior-year period — down 120.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-23K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Serina Therapeutics, and consider following SER for alerts when major investors trade the stock.